Pfizer Inc (PFE): PFE inks GT-drug-development deal with (...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119448
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: None

Wednesday, 03/20/2019 8:00:08 AM

Wednesday, March 20, 2019 8:00:08 AM

PFE inks GT-drug-development deal with (private) Vivet Therapeutics—lead indication is Wilson disease:

https://www.businesswire.com/news/home/20190320005198/en/

Under the terms of the transaction, Pfizer paid approximately €45 million (US$51 million) upon signing and may pay up to €560 million (US$635.8 million) inclusive of the option exercise payment and subject to certain clinical, regulatory, and commercial milestones. Pfizer can exercise its option to acquire 100% of Vivet following the company’s delivery of certain data from the Phase I/II clinical trial for VTX-801. As part of the transaction, Pfizer senior executive Monika Vnuk, M.D., Vice President, Worldwide Business Development, will join Vivet’s Board of Directors. Other terms of the transaction were not disclosed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”